Retatrutide vs Ozempic & Wegovy: 24.2% vs ~15% Weight Loss, Explained

Almost every "retatrutide vs Ozempic" or "retatrutide vs Wegovy" search hides a second question the searcher hasn't quite asked yet: aren't Ozempic and Wegovy the same thing? They are. So before the retatrutide comparison makes any sense, the brand names have to be untangled — because comparing retatrutide to "Ozempic" and "Wegovy" as if they were two rival drugs is comparing it to one drug wearing two labels.

This is written for research and educational purposes. It reports published trial data; it is not medical advice, and retatrutide is a research compound, not an approved medication.

Are Ozempic and Wegovy the same drug?

Yes — and this is the single most important fact for making sense of any comparison. Ozempic and Wegovy are both brand names for semaglutide, the same molecule made by the same manufacturer (Novo Nordisk). What differs is the label each brand is approved and marketed under, and the dose each is titrated to. ^[2]

So when people quote different weight-loss figures for "Ozempic" versus "Wegovy," they are usually seeing the same drug at different doses studied for different purposes. Wegovy's ~15% headline comes from the STEP 1 obesity trial, where semaglutide was titrated to 2.4 mg specifically for weight management. ^[2] Ozempic's weight numbers come from diabetes trials at lower doses, where weight loss was a secondary outcome rather than the endpoint. The molecule is identical; the packaging and the dosing intent are not.

Everything below, therefore, is really retatrutide vs semaglutide — with the Ozempic/Wegovy distinction folded in wherever it changes the practical picture.

Is retatrutide the same as Ozempic?

No. This is the other half of the confusion, and the answer is cleaner. Ozempic (and Wegovy) is semaglutide, a single GLP-1 receptor agonist — it activates one receptor. Retatrutide (LY3437943) is an investigational triple agonist that activates three receptors — GLP-1, GIP, and glucagon — with a single molecule. ^[3] They are not the same compound, not the same mechanism, and not even the same regulatory status: semaglutide is FDA-approved, retatrutide is not.

That distinction is the whole reason the numbers diverge. Semaglutide works one lever; retatrutide works three. Which brings us to the figure everyone actually came for.

Retatrutide vs Ozempic/Wegovy: the weight-loss numbers

On published mean weight-loss data, retatrutide's figures are the largest reported for this class of compound. Here is the honest side-by-side — remembering that Ozempic and Wegovy are both semaglutide.

The headline gap is 24.2% versus ~15% — retatrutide's mean weight-loss figure is roughly 60% larger than the Wegovy-dose semaglutide number. ^[1] Against Ozempic's lower-dose weight numbers, the gap is wider still, because Ozempic is not dosed to maximize weight loss in the first place.

Two caveats keep this honest. First, these are separate trials — different participants, durations, and designs — not a head-to-head study, so the percentages can't be treated as if they came from the same experiment. Second, "Ozempic" and "Wegovy" are the same semaglutide; if you see a chart pitting all three against each other as distinct drugs, it's built on a misunderstanding. The head-to-head that actually exists in the literature is retatrutide's mechanism-driven lead over the single-receptor compound behind both brands. For the deeper dive on that specific pairing, see retatrutide vs semaglutide.

Why retatrutide's number is bigger: mechanism

The efficacy gap isn't a formulation trick — it's receptor coverage. Semaglutide, the drug in Ozempic and Wegovy, is a pure GLP-1 agonist: it suppresses appetite, slows gastric emptying, and improves glucose handling through a single receptor. That one lever is enough to reach ~15% at the Wegovy dose. ^[2]

Retatrutide keeps all of that and adds two more arms. ^[3]

GIP appears to amplify GLP-1's effects rather than act alone, which is widely thought to be why dual agonism outperformed pure GLP-1 agonism in earlier readouts. ^[3] Glucagon is the genuinely novel arm: on its own it raises blood glucose, but paired with strong incretin coverage its contribution — energy expenditure and lipid mobilization — is retained while the incretin arms offset the glycemic penalty. In plain terms, semaglutide works mainly on the intake side of energy balance; retatrutide adds a lever on the output side. That is the mechanistic reason the trial numbers separate.

Do retatrutide, Ozempic, and Wegovy have the same side effects?

The tolerability story is more alike than different, because all three lean on GLP-1 activation. Both compounds are dominated by dose-dependent gastrointestinal effects — nausea, diarrhea, constipation, reduced appetite — that cluster during dose escalation and then ease at a stable dose. ^[1] This is the GLP-1-class signature, and it is why both semaglutide and retatrutide are titrated gradually rather than started at the target dose.

Because Ozempic and Wegovy are the same molecule, their side-effect types are identical; Wegovy's higher 2.4 mg dose simply tends to surface them more than Ozempic's lower glycemic-control doses. The mechanism is the same, the intensity tracks the dose.

The one notable difference from retatrutide's data is a skin-sensation effect (dysesthesia — tingling or altered sensation) reported at higher doses in its Phase 2 trial, which is not a prominent feature of semaglutide's profile. ^[1] As with every figure here, these are trial-reported findings describing study populations, not predictions for any individual.

Why the GI effects happen — and why they fade

The nausea isn't incidental; it's a direct extension of the mechanism shared by all three. GLP-1 activation slows gastric emptying, which is part of how these compounds reduce appetite — and the same slowing is what produces nausea when it changes too abruptly. That is why effects are worst during dose escalation, when exposure is moving fastest, and why they settle once the dose and plasma level stabilize. The stepwise titration schedule exists precisely to give the system time to adapt at each level. ^[1]

Dosing cadence: how retatrutide, Ozempic, and Wegovy compare

Here the three are nearly identical in shape. All are once-weekly subcutaneous compounds with multi-day half-lives — retatrutide ~6 days, semaglutide ~7 days ^[4] — which is exactly what makes weekly dosing viable and means all of them take about a month of accumulation to reach steady state. All use gradual dose titration.

The doses look wildly different — 12 mg versus 2.4 mg — but that's a comparison of two different molecules, not two different potencies of the same one. Milligram-for-milligram numbers across different peptides mean little; what matters is the effect each reaches at its own studied dose. Where Ozempic and Wegovy genuinely differ from each other is only the top of the ladder: Wegovy climbs to 2.4 mg for weight management, Ozempic stops lower for glycemic control. Same drug, different destination on the titration schedule.

If you understand one compound's weekly cadence, you understand all three. The pharmacokinetics that drive the ~6-day retatrutide half-life — and the roughly month-long ramp to steady state — are covered in the complete retatrutide guide.

What the response rates showed

Averages hide variation, so the sharper question is how consistently each worked. Semaglutide's STEP 1 trial reported that a large majority of participants crossed meaningful thresholds — roughly 86% reached at least 5% loss, about 69% reached 10%, and about half reached 15%. ^[2] Retatrutide's Phase 2 data reported a higher-responding distribution at the top doses, with the large majority of participants reaching clinically meaningful loss and more of them reaching the higher thresholds. ^[1]

The practical read is that both are reliable in the sense that most subjects respond; they differ in how far that response goes. That is the same conclusion the mechanism predicts — one lever versus three.

Availability: brand-name prescription vs research compound

This is where the comparison stops being about biology and becomes about how you'd actually obtain each — and it's the difference the trial numbers can't tell you.

Ozempic and Wegovy are FDA-approved prescription drugs. They are prescribed by a licensed clinician, dispensed by a pharmacy, and manufactured to pharmaceutical standards. Their identity and purity are not something a buyer has to verify — that's what approval and pharmacy dispensing guarantee. What you trade for that certainty is access friction: prescriptions, insurance, and, at various points, supply shortages.

Retatrutide is investigational and not approved for human use. It is available only through the research-compound market, which means sourcing quality becomes the decisive variable — the role the pharmacy and the FDA play for semaglutide falls to you and your supplier. The single most important thing to verify is a batch-matched certificate of analysis tied to a specific lot: mass by HPLC, identity by mass spectrometry, a measured purity figure, and a characterized impurity profile — ideally confirmed by independent third-party testing rather than the manufacturer's own numbers alone.

Modern Bio's retatrutide ships with a batch-matched COA on every vial — the closest a research compound comes to the identity assurance an approved prescription provides by default.

"Why retatrutide is better than Ozempic" — the honest version

It's a common search, so it deserves a precise answer rather than a slogan. On the evidence:

• On mean weight loss, retatrutide's trial figures are larger — 24.2% vs ~15% — and the gap is bigger still against Ozempic's lower weight-management ceiling. ^{[1] [2]}
• On mechanism, retatrutide is more comprehensive — three complementary receptors versus one. ^[3]
• On maturity and access, semaglutide (Ozempic/Wegovy) is clearly ahead — years of characterization, regulatory approval, and pharmacy dispensing that a research compound cannot match.

So "better" depends entirely on the axis. For peak studied efficacy and the newest mechanism, retatrutide leads. For an established, approved, extensively characterized single-receptor reference, semaglutide — under either brand — is the standard. A credible comparison names the axis instead of declaring a universal winner. And retatrutide is not the only compound in this conversation: the dual GLP-1/GIP agonist tirzepatide sits between them at ~21%, covered in retatrutide vs tirzepatide.

Which one suits which research question

Semaglutide is the established reference — the single-receptor compound with the deepest characterization and the longest track record, which is exactly why it's the drug behind both Ozempic and Wegovy. Retatrutide is the efficacy frontier — the newest mechanism and the largest trial effect, the compound to study when the question is about maximal response. Many research programs study both precisely to map the gap between one lever and three.

The bottom line

Ozempic and Wegovy are one drug — semaglutide — under two labels, separated only by dose and approved use. Retatrutide is a different molecule and a different mechanism: a triple agonist whose Phase 2 data (24.2%) run well ahead of semaglutide's STEP 1 figure (~15%), from separate trials, for reasons the receptor coverage predicts. ^{[1] [2] [3]} The trade is maturity and access: the brands are approved and pharmacy-dispensed; retatrutide is a research compound where a batch-matched COA does the verification a prescription otherwise would. For the full evidence base on retatrutide itself, start with the complete retatrutide guide.

For research and educational purposes only. Not medical advice. Ozempic and Wegovy are FDA-approved prescription medications referenced here for comparison; retatrutide is investigational and is not approved for human use. Cross-compound figures are drawn from separate clinical trials, not head-to-head studies.